Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)
Executive Summary
The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.
You may also be interested in...
Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision
United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.